JP2004517049A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004517049A5 JP2004517049A5 JP2002525102A JP2002525102A JP2004517049A5 JP 2004517049 A5 JP2004517049 A5 JP 2004517049A5 JP 2002525102 A JP2002525102 A JP 2002525102A JP 2002525102 A JP2002525102 A JP 2002525102A JP 2004517049 A5 JP2004517049 A5 JP 2004517049A5
- Authority
- JP
- Japan
- Prior art keywords
- solvate
- salt
- functional derivative
- physiologically functional
- ylidene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims 6
- 239000011780 sodium chloride Substances 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000001404 mediated Effects 0.000 claims 2
- HCKUFQKWZDUIHQ-UHFFFAOYSA-N 1-[4-[2-(4-chloro-5-hydroxy-2-oxo-6-propan-2-ylindol-3-yl)hydrazinyl]phenyl]-N-methylmethanesulfonamide Chemical compound C1=CC(CS(=O)(=O)NC)=CC=C1N\N=C/1C2=C(Cl)C(O)=C(C(C)C)C=C2NC\1=O HCKUFQKWZDUIHQ-UHFFFAOYSA-N 0.000 claims 1
- -1 5-Methyl-1,3,4-thiadiazol-2-yl Chemical group 0.000 claims 1
- UGKCASUMDGHTLI-UVTDQMKNSA-N N-[4-[[(Z)-(2-oxo-1H-indol-3-ylidene)methyl]amino]phenyl]methanesulfonamide Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1N\C=C/1C2=CC=CC=C2NC\1=O UGKCASUMDGHTLI-UVTDQMKNSA-N 0.000 claims 1
- 101700043017 NTRK1 Proteins 0.000 claims 1
- 102000030951 Phosphotransferases Human genes 0.000 claims 1
- 108091000081 Phosphotransferases Proteins 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- YIYZHARUXWKUEN-UHFFFAOYSA-N benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1.NS(=O)(=O)C1=CC=CC=C1 YIYZHARUXWKUEN-UHFFFAOYSA-N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 239000003226 mitogen Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Claims (6)
- {4-[(2Z)-2-(4-クロロ-5-ヒドロキシ-6-イソプロピル-2-オキソ-1,2-ジヒドロ-3H-インドール-3-イリデン)ヒドラジノ]フェニル}-N-メチルメタンスルホンアミド;
N-(4-{[(Z)-(2-オキソ-1,2-ジヒドロ-3H-インドール-3-イリデン)メチル]アミノ}フェニル)メタンスルホンアミド;
4-{[(Z)-(2-オキソ-1,2-ジヒドロ-3H-インドール-3-イリデン)メチル]アミノ}-N-(2-ピリジニル)ベンゼンスルホンアミド;
N-(5-メチル-1,3,4-チアジアゾール-2-イル)-4-{[(Z)-(2-オキソ-1,2-ジヒドロ-3H-インドール-3-イリデン)メチル]アミノ}ベンゼンスルホンアミド;3-{[(Z)-(2-オキソ-1,2-ジヒドロ-3H-インドール-3-イリデン)メチル]アミノ}ベンゼンスルホンアミドからなる群から選択される化合物;及びその塩、溶媒和物又は生理学的機能性誘導体。 - 治療的有効量の請求項1もしくは2記載の化合物又はその塩、溶媒和物、もしくは生理学的機能性誘導体、及び1以上の製薬上許容されるキャリアー、希釈剤、及び添加剤を含有する医薬組成物。
- 治療に使用する、請求項1もしくは2記載の化合物又はその塩、溶媒和物、もしくは生理学的機能性誘導体。
- 不適切なTrkA活性が介在する障害の治療に使用するための医薬の調製における、請求項1もしくは2記載の化合物又はその塩、溶媒和物、もしくは生理学的機能性誘導体の使用。
- 不適切な分裂促進因子活性化型キナーゼ活性が介在する障害の治療に使用するための医薬の調製における、請求項1もしくは2記載の化合物又はその塩、溶媒和物、もしくは生理学的機能性誘導体の使用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23005000P | 2000-09-01 | 2000-09-01 | |
PCT/US2001/026423 WO2002020479A1 (en) | 2000-09-01 | 2001-08-23 | Substituted oxindole derivatives as tyrosine kinase inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2004517049A JP2004517049A (ja) | 2004-06-10 |
JP2004517049A5 true JP2004517049A5 (ja) | 2005-04-07 |
Family
ID=22863755
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002525102A Pending JP2004517049A (ja) | 2000-09-01 | 2001-08-23 | チロシンキナーゼ阻害剤としての置換オキシインドール誘導体 |
Country Status (5)
Country | Link |
---|---|
US (2) | US7071217B2 (ja) |
EP (1) | EP1339680A1 (ja) |
JP (1) | JP2004517049A (ja) |
AU (1) | AU2001288374A1 (ja) |
WO (1) | WO2002020479A1 (ja) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001288374A1 (en) * | 2000-09-01 | 2002-03-22 | Glaxo Group Limited | Substituted oxindole derivatives as tyrosine kinase inhibitors |
WO2003027102A1 (en) * | 2001-09-27 | 2003-04-03 | Allergan, Inc. | 3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors |
UA80447C2 (en) | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
SI1556083T1 (sl) | 2002-10-08 | 2011-05-31 | Rinat Neuroscience Corp | Postopki za zdravljenje postoperativne bolečine z dajanjem protitelesa proti živčnemu rastnemu faktorju in sestavki, ki ga vsebujejo |
US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
HUE026089T2 (hu) | 2002-12-24 | 2016-05-30 | Rinat Neuroscience Corp | NGF elleni antitestek és eljárás alkalmazásukra |
US9498530B2 (en) | 2002-12-24 | 2016-11-22 | Rinat Neuroscience Corp. | Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same |
ATE491444T1 (de) | 2003-02-19 | 2011-01-15 | Rinat Neuroscience Corp | Verfahren zur behandlung von schmerzen durch verabreichung eines nervenwachstumsfaktor- antagonisten und eines nsaid und diese enthaltende zusammensetzung |
WO2005058913A1 (en) | 2003-12-18 | 2005-06-30 | Janssen Pharmaceutica N.V. | Pyrido- and pyrimidopyrimidine derivatives as anti- proliferative agents |
CA2562024C (en) | 2004-04-07 | 2014-05-27 | Rinat Neuroscience Corp. | Methods for treating bone cancer pain by administering a nerve growth factor antagonist |
WO2005118551A2 (en) * | 2004-05-28 | 2005-12-15 | Ligand Pharmaceuticals Inc. | Thrombopoietin activity modulating compounds and methods |
JP4728340B2 (ja) * | 2004-10-25 | 2011-07-20 | リガンド・ファーマシューティカルズ・インコーポレイテッド | トロンボポエチン活性を変調する化合物および変調方法 |
NI200700147A (es) | 2004-12-08 | 2019-05-10 | Janssen Pharmaceutica Nv | Derivados de quinazolina inhibidores de cinasas dirigidos a multip |
SI1846394T1 (sl) | 2005-02-04 | 2012-06-29 | Astrazeneca Ab | Pirazolilaminopiridinski derivati uporabni kot kinazni inhibitorji |
KR101362621B1 (ko) | 2005-02-16 | 2014-02-13 | 아스트라제네카 아베 | 화합물 |
WO2006123113A2 (en) | 2005-05-16 | 2006-11-23 | Astrazeneca Ab | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors |
ITRM20050290A1 (it) | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
EP1945631B8 (en) | 2005-10-28 | 2013-01-02 | AstraZeneca AB | 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer |
US7879318B2 (en) * | 2006-01-23 | 2011-02-01 | Mcw Research Foundation, Inc. | Method of reducing the effects of ischemia by administration of a thrombopoietin receptor ligand |
EP2009005A4 (en) | 2006-04-19 | 2010-06-02 | Astellas Pharma Inc | AZOLECARBOXAMIDE DERIVATIVE |
AU2007274284B2 (en) | 2006-07-13 | 2012-04-26 | Janssen Pharmaceutica N.V. | Mtki quinazoline derivatives |
TW200826937A (en) * | 2006-11-01 | 2008-07-01 | Astrazeneca Ab | New use |
TW200823196A (en) * | 2006-11-01 | 2008-06-01 | Astrazeneca Ab | New use |
JP5385268B2 (ja) * | 2007-06-21 | 2014-01-08 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | インドリン−2−オンおよびアザ−インドリン−2−オン |
DK2185562T3 (en) | 2007-07-27 | 2016-02-22 | Janssen Pharmaceutica Nv | PYRROLOPYRIMIDINES SUITABLE FOR TREATING PROLIFERATIVE DISEASES |
PL2206707T3 (pl) | 2007-10-24 | 2015-01-30 | Astellas Pharma Inc | Związek azolokarboksamidowy lub jego sól |
CA2711865A1 (en) | 2008-01-11 | 2009-07-16 | Astellas Pharma Inc. | A pathological animal model simultaneously developing testicular pain or discomfort behaviors and urinary frequency |
TWI585088B (zh) | 2012-06-04 | 2017-06-01 | 第一三共股份有限公司 | 作爲激酶抑制劑之咪唑并[1,2-b]嗒衍生物 |
US20230348608A1 (en) | 2022-04-27 | 2023-11-02 | Regeneron Pharmaceuticals, Inc. | Treatment Of Arthropathy Based Upon Stratification Of Osteoarthritis Polygenic Risk Score |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9718913D0 (en) * | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
US6269086B1 (en) * | 1998-02-27 | 2001-07-31 | Legerity, Inc. | Arrangement and method for selectable time/frequency division multiplex communication |
DE19824922A1 (de) * | 1998-06-04 | 1999-12-09 | Boehringer Ingelheim Pharma | Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel |
US6498176B1 (en) * | 1999-03-04 | 2002-12-24 | Smithklinebeecham Corporation | 3-(anilinomethylene) oxindoles as protein tyrosine kinase and protein serine/threonine kinase inhibitors |
US6624171B1 (en) * | 1999-03-04 | 2003-09-23 | Smithkline Beecham Corporation | Substituted aza-oxindole derivatives |
GB9904933D0 (en) | 1999-03-04 | 1999-04-28 | Glaxo Group Ltd | Compounds |
US6492398B1 (en) * | 1999-03-04 | 2002-12-10 | Smithkline Beechman Corporation | Thiazoloindolinone compounds |
US6620818B1 (en) * | 2000-03-01 | 2003-09-16 | Smithkline Beecham Corporation | Method for reducing the severity of side effects of chemotherapy and/or radiation therapy |
AU2001288374A1 (en) * | 2000-09-01 | 2002-03-22 | Glaxo Group Limited | Substituted oxindole derivatives as tyrosine kinase inhibitors |
ES2275021T3 (es) | 2001-09-27 | 2007-06-01 | Smithkline Beecham Corporation | Derivados de azoxoindol como inhibidores de trk proteina quinasa para el tratamiento de cancer y dolor cronico. |
-
2001
- 2001-08-23 AU AU2001288374A patent/AU2001288374A1/en not_active Abandoned
- 2001-08-23 WO PCT/US2001/026423 patent/WO2002020479A1/en active Application Filing
- 2001-08-23 US US10/362,743 patent/US7071217B2/en not_active Expired - Fee Related
- 2001-08-23 EP EP01968099A patent/EP1339680A1/en not_active Withdrawn
- 2001-08-23 JP JP2002525102A patent/JP2004517049A/ja active Pending
-
2005
- 2005-06-09 US US11/148,635 patent/US7338966B2/en not_active Expired - Fee Related
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2004517049A5 (ja) | ||
JP6021805B2 (ja) | 腫瘍治療剤 | |
JP2004517087A5 (ja) | ||
JP2005508337A5 (ja) | ||
RU2004117887A (ru) | Ариланилиновые агонисты бета2 адренергических рецепторов | |
RU2008112221A (ru) | Соединения ряда изоиндолимидов, их композиции и способы применения | |
JP2005523922A5 (ja) | ||
JP2006509749A5 (ja) | ||
JP2014502979A5 (ja) | ||
JP2008534453A5 (ja) | ||
JP2009501745A5 (ja) | ||
RU2004104625A (ru) | Аналоги простагландинов в качестве агонистов рецептора ep4 | |
RU2010129272A (ru) | Производные аминотриазола в качестве агонистов alх | |
JP2010501478A5 (ja) | ||
AU2016252860B2 (en) | Compositions and methods for inhibiting kinases | |
MXPA04002338A (es) | Derivados de carbazol y su uso como antagonistas receptores del npy5. | |
RU2007120710A (ru) | Способ лечения рака и/или лейкоза и применяемая в нем фармацевтическая композиция | |
AU2011227398A1 (en) | Modulators of Hec1 activity and methods therefor | |
TW201912153A (zh) | 用於治療b型肝炎的化合物、醫藥組合物及方法 | |
CA2635093A1 (en) | Derivatives of sulindac, use thereof and preparation thereof | |
JPWO2020038415A5 (ja) | ||
JP2008508350A5 (ja) | ||
RU2004119963A (ru) | Ингибиторы вич интегразы | |
JP2007501284A5 (ja) | ||
JP2006516626A5 (ja) |